智通财经获悉，晶泰控股(02228)高开15%，截至发稿，涨15%，报7.59港元，成交额1.66亿港元。 消息面上，8月5日，晶泰科技宣布与DoveTree完成总订单规模约470亿港元(59.9亿美元)的管线合作签 约，成为2025年中国AI制药领域金额最大的BD交易之一。DoveTree获得合作产品的全球独家开发与商 业化权利，而晶泰则负责利用其 "AI+机器人"端到端平台，针对肿瘤、自身免疫病、神经系统疾病及代 谢失调领域的靶点，开发小分子与抗体药物。 目前，晶泰科技已收到最终协议项下约定的5100万美元的首付款。在最终协议条款规限下，晶泰科技有 权获得4900万美元的进一步付款(180天内支付)，并有资格获得金额达58.9亿美元的潜在监管里程碑及商 业里程碑付款，以及基于产品年度净销售额的潜在个位数百分点的特许权使用费。 本文源自：智通财经网 ...

Core Viewpoint - Jingtai Holdings (02228) experienced a significant increase in stock price, opening 15% higher and reaching HKD 7.59 with a trading volume of HKD 1.66 billion, following a major partnership announcement in the AI pharmaceutical sector [1] Group 1: Partnership Details - On August 5, Jingtai Technology announced the completion of a pipeline cooperation agreement with DoveTree, with a total order scale of approximately HKD 470 billion (USD 59.9 billion), marking one of the largest business development transactions in China's AI pharmaceutical field by 2025 [1] - DoveTree has obtained global exclusive development and commercialization rights for the cooperative products, while Jingtai is responsible for utilizing its "AI + robotics" end-to-end platform to develop small molecules and antibody drugs targeting oncology, autoimmune diseases, neurological disorders, and metabolic disorders [1] Group 2: Financial Terms - Jingtai Technology has received an initial payment of USD 51 million as stipulated in the final agreement [1] - Under the terms of the final agreement, Jingtai is entitled to receive an additional payment of USD 49 million (to be paid within 180 days) and is eligible for potential regulatory and commercial milestone payments amounting to USD 5.89 billion, as well as potential single-digit percentage royalties based on annual net sales of the products [1]

目前，晶泰科技已收到最终协议项下约定的5100万美元的首付款。在最终协议条款规限下，晶泰科技有 权获得4900万美元的进一步付款(180天内支付)，并有资格获得金额达58.9亿美元的潜在监管里程碑及商 业里程碑付款，以及基于产品年度净销售额的潜在个位数百分点的特许权使用费。 智通财经APP获悉，晶泰控股(02228)高开15%，截至发稿，涨15%，报7.59港元，成交额1.66亿港元。 消息面上，8月5日，晶泰科技宣布与DoveTree完成总订单规模约470亿港元(59.9亿美元)的管线合作签 约，成为2025年中国AI制药领域金额最大的BD交易之一。DoveTree获得合作产品的全球独家开发与商 业化权利，而晶泰则负责利用其 "AI+机器人"端到端平台，针对肿瘤、自身免疫病、神经系统疾病及代 谢失调领域的靶点，开发小分子与抗体药物。 ...